Journey Medical Corporation, a pharmaceutical firm established in Scottsdale, Arizona in 2014 (and previously known as Coronado Dermatology, Inc.), is dedicated to the development and market introduction of treatments for skin conditions across the United States. Their product line encompasses key dermatological therapies such as Qbrexza, a medicated cloth wipe for managing primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe, persistent acne; Targadox, an oral doxycycline medication used as an additional treatment for severe acne; Ximino, an oral minocycline drug addressing moderate to severe acne; and Exelderm, offered as a topical cream and solution. Furthermore, the company distributes doxycycline hyclate tablets, minocycline hydrochloride capsules, and sulconazole nitrate cream and solution.
Journey Medical Corporation to Participate in September 2026 Investor Conferences
Journey Medical Corporation announced that CEO Claude Maraoui will participate in two investor conferences in September 2026.
The events include the Lake Street Capital Markets BIG10 Conference and the H.C. Wainwright Global Investment Conference, both in New York City.
A webcast of the H.C. Wainwright presentation will be available on the company's website for approximately 30 days.